Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cullinan Therapeutics Inc (CGEM)

Cullinan Therapeutics Inc (CGEM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 919,420
  • Shares Outstanding, K 58,228
  • Annual Sales, $ 0 K
  • Annual Income, $ -153,160 K
  • EBIT $ -187 M
  • EBITDA $ -187 M
  • 60-Month Beta -0.12
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.48

Options Overview Details

View History
  • Implied Volatility 107.44% ( +13.57%)
  • Historical Volatility 55.87%
  • IV Percentile 69%
  • IV Rank 54.20%
  • IV High 164.51% on 12/12/23
  • IV Low 39.91% on 08/20/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 6
  • Put/Call OI Ratio 2.14
  • Today's Open Interest 1,872
  • Open Int (30-Day) 4,087

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.82
  • Number of Estimates 7
  • High Estimate -0.74
  • Low Estimate -1.09
  • Prior Year -0.54
  • Growth Rate Est. (year over year) -51.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.15 +1.02%
on 11/05/24
17.98 -14.88%
on 10/16/24
-0.93 (-5.73%)
since 10/14/24
3-Month
14.86 +2.96%
on 10/10/24
19.89 -23.08%
on 09/03/24
-0.94 (-5.79%)
since 08/14/24
52-Week
7.64 +100.26%
on 12/12/23
30.19 -49.32%
on 05/07/24
+5.81 (+61.22%)
since 11/14/23

Most Recent Stories

More News
Cullinan Therapeutics Announces New Preclinical Data for CLN-978 and Global Phase 1b Study in Systemic Lupus Erythematosus

Cullinan will present new preclinical data for CLN-978 and details of a Phase 1b study in lupus at ACR 2024.Quiver AI SummaryCullinan Therapeutics, Inc. announced that it will present new preclinical data...

CGEM : 15.30 (-3.10%)
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

CGEM : 15.30 (-3.10%)
Cullinan Therapeutics: Q3 Earnings Snapshot

Cullinan Therapeutics: Q3 Earnings Snapshot

CGEM : 15.30 (-3.10%)
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

CGEM : 15.30 (-3.10%)
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

CGEM : 15.30 (-3.10%)
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

CGEM : 15.30 (-3.10%)
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

CGEM : 15.30 (-3.10%)
REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

/PRNewswire/ -- Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Oncology, Inc., announced today the launch of the REZILIENT3 trial...

CGEM : 15.30 (-3.10%)
Why Shares of Cullinan Oncology Jumped This Week

The company's presentation at a conference got the attention of analysts and investors.

CGEM : 15.30 (-3.10%)
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Completed agreement for strategic collaboration to jointly develop and commercialize CLN-081 with Taiho Pharmaceutical Presented updated Phase 1/2a data...

CGEM : 15.30 (-3.10%)

Business Summary

Cullinan Therapeutics Inc. is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. The company's product pipeline consists CLN-978. Cullinan Therapeutics Inc., formerly known as Cullinan Oncology Inc., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 16.88
2nd Resistance Point 16.54
1st Resistance Point 15.92
Last Price 15.30
1st Support Level 14.96
2nd Support Level 14.62
3rd Support Level 14.00

See More

52-Week High 30.19
Fibonacci 61.8% 21.58
Fibonacci 50% 18.91
Fibonacci 38.2% 16.25
Last Price 15.30
52-Week Low 7.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar